Noradrenalin Abcur (Noradrenaline Tartrate)

The drug acts as a direct agonist at alpha‑1 adrenergic receptors, causing strong vasoconstriction that raises systemic vascular resistance and arterial pressure. It also stimulates beta‑1 receptors modestly, which can enhance heart contractility, together stabilizing hemodynamics in shock.

The dosage is individualized and set by the prescribing clinician based on the patient’s hemodynamic status, target blood pressure, and response to therapy. Infusion rates are titrated to achieve the desired mean arterial pressure while monitoring for adverse effects.

Safety data for Noradrenalin Tartrate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed), and import documentation.

Noradrenalin is considered the first‑line vasopressor for most shock states due to its potent α‑adrenergic activity and relatively predictable hemodynamic profile. Compared with agents like dopamine or phenylephrine, it offers stronger vasoconstriction with less tachyarrhythmic risk, making it preferred in septic shock.

The product should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen. Before use, inspect the vial for particulate matter and ensure the solution is at room temperature if required by the administration protocol.

It is given as an intravenous infusion, typically diluted in a compatible carrier solution and delivered through a calibrated infusion pump. Administration is performed by trained healthcare professionals in a monitored setting such as an ICU.

Serious risks include severe hypertension, myocardial ischemia, life‑threatening arrhythmias, and peripheral tissue necrosis from extravasation. Continuous cardiovascular monitoring and prompt management of any adverse signs are essential during therapy.

Patients with known hypersensitivity to norepinephrine or its excipients, those with uncontrolled mesenteric or peripheral ischemia, and individuals where vasoconstriction could worsen organ perfusion should not receive this medication, unless a clinician determines the benefits outweigh the risks.